Tg Therapeutics (TGTX) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $390.9 million.
- Tg Therapeutics' Net Income towards Common Stockholders rose 1000623.06% to $390.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $447.5 million, marking a year-over-year increase of 321281.3%. This contributed to the annual value of $23.4 million for FY2024, which is 8452.49% up from last year.
- Per Tg Therapeutics' latest filing, its Net Income towards Common Stockholders stood at $390.9 million for Q3 2025, which was up 1000623.06% from $28.2 million recorded in Q2 2025.
- In the past 5 years, Tg Therapeutics' Net Income towards Common Stockholders ranged from a high of $390.9 million in Q3 2025 and a low of -$94.0 million during Q4 2021
- Moreover, its 5-year median value for Net Income towards Common Stockholders was -$36.6 million (2022), whereas its average is -$6.2 million.
- In the last 5 years, Tg Therapeutics' Net Income towards Common Stockholders crashed by 9660.49% in 2024 and then skyrocketed by 1000623.06% in 2025.
- Tg Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$94.0 million in 2021, then increased by 14.49% to -$80.4 million in 2022, then soared by 82.07% to -$14.4 million in 2023, then soared by 261.92% to $23.3 million in 2024, then soared by 1574.7% to $390.9 million in 2025.
- Its Net Income towards Common Stockholders was $390.9 million in Q3 2025, compared to $28.2 million in Q2 2025 and $5.1 million in Q1 2025.